CURRENT
ISSUE
1574
June 17, 2019
Mild to moderate psoriasis can be treated with topical drugs or with phototherapy. Patients with moderate to severe disease generally require systemic therapy....  Continue reading
More from Issue 1574
Previous Issue: 1573      June 3, 2019
Coming Soon
Tafenoquine (Arakoda and Krintafel) for Malaria
Colon Cancer Screening
Estradiol/Progesterone (Bijuva) for Menopause
Cyclosporine 0.09% Solution (Cequa) for Dry Eye Disease
Drugs for Tobacco Dependence
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
Featured Article
FROM
ISSUE
1573
The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa (Skyrizi – Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) and tildrakizumab (Ilumya) were approved earlier. ... Continue reading